Optic IconOptic Logo
|
SearchCollectionsBenchmarks

Camrelizumab + Rivoceranib

1 product

5 abstracts

2 targets

Target
VEGFR2
Target
VEGFR1
Abstract
Comparison of checkpoint inhibitor–based regimens as first-line therapy in advanced hepatocellular carcinoma: A Frequentist Network meta-analysis of randomized clinical trials.
Org: Saint Mary's and Saint Clare's Hospital, Howard University Hospital, Reg Cancer Center at St Michael's Medical Center, St. Michael's Medical Ctr,
Abstract
A phase Ib/II study to evaluate surufatinib combined with camrelizumab and chemotherapy in the second-line treatment of advanced colorectal cancer: Phase Ib results.
Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China,
Abstract
A multicenter phase I/II trial of induction chemotherapy followed by camrelizumab, apatinib, plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer.
Org: Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, Guangzhou Institute of Respiratory Health, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases, the First Affiliated Hospital of Guangzhou Medical University,
Abstract
A retrospective cohort study examining the effects of anti–PD-1 antibody in combination with apatinib in patients previously treated for HER2-negative advanced gastric/gastroesophageal junction cancer.
Org: Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Henan Cancer Hospital, Zhengzhou, China, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital,
Abstract
Comparison of first-line treatments for recurrent or metastatic nasopharyngeal carcinoma based on phase 3 randomized clinical trials.
Org: Department of Radiotherapy, Jiangsu Cancer Hospital, Nanjing, Jiangsu, China, Yunnan Cancer Hospital, Kunming, Yunnan, China, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China, Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine, Durham, NC,
Product
camrelizumab + rivoceranib